Literature DB >> 11264457

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

A Carlsson1, N Waters, S Holm-Waters, J Tedroff, M Nilsson, M L Carlsson.   

Abstract

In spite of its proven heuristic value, the dopamine hypothesis of schizophrenia is now yielding to a multifactorial view, in which the other monoamines as well as glutamate and GABA are included, with a focus on neurotransmitter interactions in complex neurocircuits. The primary lesion(s) in schizophrenia does not necessarily involve any of these neurotransmitters directly but could deal with a more general defect, such as a faulty connectivity of developmental origin. Nevertheless, a precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264457     DOI: 10.1146/annurev.pharmtox.41.1.237

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  175 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

2.  Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex.

Authors:  Joanna P Tyszkiewicz; Zhenglin Gu; Xun Wang; Xiang Cai; Zhen Yan
Journal:  J Physiol       Date:  2003-11-28       Impact factor: 5.182

3.  Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors.

Authors:  Lin Pei; Frank J S Lee; Anna Moszczynska; Brian Vukusic; Fang Liu
Journal:  J Neurosci       Date:  2004-02-04       Impact factor: 6.167

4.  Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.

Authors:  Tsuyoshi Miyakawa; Lorene M Leiter; David J Gerber; Raul R Gainetdinov; Tatyana D Sotnikova; Hongkui Zeng; Marc G Caron; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

5.  Could stress cause psychosis in individuals vulnerable to schizophrenia?

Authors:  Cheryl Corcoran; Lilianne Mujica-Parodi; Scott Yale; David Leitman; Dolores Malaspina
Journal:  CNS Spectr       Date:  2002-01       Impact factor: 3.790

6.  Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex.

Authors:  Guojun Chen; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 7.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 8.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.

Authors:  Vinita Jagannath; Miriam Gerstenberg; Christoph U Correll; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

10.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.

Authors:  J C Winter; J R Eckler; R A Rabin
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.